SAM
SGMT icon

Smartleaf Asset Management’s Sagimet Biosciences SGMT Stock Holding History

Smartleaf Asset Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.55K Buy
1,000
+500
+100% +$2.79K ﹤0.01% 2701
2025
Q4 		$2.92K Buy
+500
New +$3.59K ﹤0.01% 2871

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Smartleaf Asset Management's SGMT Position: Q1 2026 in Review

Smartleaf Asset Management increased its Sagimet Biosciences (SGMT) stake by 100% in Q1 2026, buying an estimated $2.79K and bringing the position to 1,000 shares worth $4.55K. The position accounts for ﹤0.01% of the portfolio, ranked #2701.

Smartleaf Asset Management first reported a position in SGMT in Q4 2025 and has held it in 2 quarters since. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Smartleaf Asset Management held 1,000 shares of Sagimet Biosciences worth $4.55K as of Q1 2026.
  • Smartleaf Asset Management bought 500 Sagimet Biosciences shares in Q1 2026, an estimated $2.79K.
  • Sagimet Biosciences made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #2701 holding.
  • Smartleaf Asset Management first reported a position in Sagimet Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.